Literature DB >> 23265701

Outcome of second-line chemotherapy for biliary tract cancer.

John Bridgewater, Daniel Palmer, David Cunningham, Tim Iveson, Roopinder Gillmore, Justin Waters, Mark Harrison, Harpreet Wasan, Pippa Corrie, Juan Valle.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23265701     DOI： 10.1016/j.ejca.2012.11.024

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  16 in total

Review 1.  Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications.

Authors:  Daniel H Ahn; Tanios Bekaii-Saab
Journal:  J Gastrointest Oncol       Date:  2017-04

Review 2.  New Horizons for Precision Medicine in Biliary Tract Cancers.

Authors:  Juan W Valle; Angela Lamarca; Lipika Goyal; Jorge Barriuso; Andrew X Zhu
Journal:  Cancer Discov       Date:  2017-08-17       Impact factor: 39.397

3.  FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma.

Authors:  Jean-Florian Guion-Dusserre; Veronique Lorgis; Julie Vincent; Leila Bengrine; Francois Ghiringhelli
Journal:  World J Gastroenterol       Date:  2015-02-21       Impact factor: 5.742

4.  Hepatic arterial infusion with oxaliplatin and 5-FU/folinic acid for advanced biliary tract cancer: a phase II study.

Authors:  M Sinn; A Nicolaou; B Gebauer; P Podrabsky; D Seehofer; J Ricke; B Dörken; H Riess; B Hildebrandt
Journal:  Dig Dis Sci       Date:  2013-03-24       Impact factor: 3.199

5.  Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index.

Authors:  Giulia Rovesti; Francesco Leone; Giovanni Brandi; Lorenzo Fornaro; Mario Scartozzi; Monica Niger; Changhoon Yoo; Francesco Caputo; Roberto Filippi; Mariaelena Casagrande; Nicola Silvestris; Daniele Santini; Luca Faloppi; Andrea Palloni; Massimo Aglietta; Caterina Vivaldi; Hyungwoo Cho; Eleonora Lai; Elisabetta Fenocchio; Federico Nichetti; Nicoletta Pella; Stefania De Lorenzo; Massimo Di Maio; Enrico Vasile; Filippo de Braud; Jae Ho Jeong; Giuseppe Aprile; Giulia Orsi; Stefano Cascinu; Andrea Casadei-Gardini
Journal:  J Gastrointest Cancer       Date:  2021-02-05

6.  Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer.

Authors:  L Fornaro; S Cereda; G Aprile; S Di Girolamo; D Santini; N Silvestris; S Lonardi; F Leone; M Milella; C Vivaldi; C Belli; F Bergamo; S E Lutrino; R Filippi; M Russano; V Vaccaro; A E Brunetti; V Rotella; A Falcone; M A Barbera; J Corbelli; G Fasola; M Aglietta; V Zagonel; M Reni; E Vasile; G Brandi
Journal:  Br J Cancer       Date:  2014-04-08       Impact factor: 7.640

7.  Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data.

Authors:  Lorenzo Fornaro; Caterina Vivaldi; Stefano Cereda; Francesco Leone; Giuseppe Aprile; Sara Lonardi; Nicola Silvestris; Daniele Santini; Michele Milella; Chiara Caparello; Gianna Musettini; Giulia Pasquini; Alfredo Falcone; Giovanni Brandi; Isabella Sperduti; Enrico Vasile
Journal:  J Exp Clin Cancer Res       Date:  2015-12-23

Review 8.  Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma.

Authors:  Pavan Najran; Angela Lamarca; Damian Mullan; Mairéad G McNamara; Thomas Westwood; Richard A Hubner; Jeremy Lawrence; Prakash Manoharan; Jon Bell; Juan W Valle
Journal:  Curr Oncol Rep       Date:  2017-07       Impact factor: 5.075

9.  Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients.

Authors:  Bum Jun Kim; Changhoon Yoo; Kyu-Pyo Kim; Jaewon Hyung; Seong Joon Park; Baek-Yeol Ryoo; Heung-Moon Chang
Journal:  Br J Cancer       Date:  2017-01-12       Impact factor: 7.640

Review 10.  The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.

Authors:  Dawn Q Chong; Andrew X Zhu
Journal:  Oncotarget       Date:  2016-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.